Is Ginkgo Bioworks Stock a Good Buy?
Biotech innovator Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) has had better…
Buy
63
CDRE Quote, Financials, Valuation and Earnings
Last price:
$35.38
Seasonality move
:
12.96%
Day range:
$34.69 - $35.48
52-week range:
$27.07 - $40.28
Dividend yield:
1.03%
P/E ratio:
37.15x
P/S ratio:
2.58x
P/B ratio:
4.52x
Volume:
345.1K
Avg. volume:
330K
1-year change:
18.03%
Market cap:
$1.4B
Revenue:
$567.6M
EPS (TTM):
$0.95
Analysts' Opinion
-
Consensus RatingCadre Holdings has received a consensus rating of Buy. The company's average rating is a Buy based on 4 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $43.83, Cadre Holdings has an estimated upside of 24.21% from its current price of $35.29.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $40.00 representing -13.35% downside risk from its current price of $35.29.
Fair Value
-
According to the consensus of 5 analysts, Cadre Holdings has 24.21% upside to fair value with a price target of $43.83 per share.
CDRE vs. S&P 500
-
Over the past 5 trading days, Cadre Holdings has underperformed the S&P 500 by -5.25% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Cadre Holdings does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Cadre Holdings revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Cadre Holdings reported revenues of $130.1M.
Earnings Growth
-
Cadre Holdings has grown year-over-year earnings for 2 quarters straight. In the most recent quarter Cadre Holdings reported earnings per share of $0.23.
Enterprise value:
1.5B
EV / Invested capital:
2.83x
Price / LTM sales:
2.58x
EV / EBIT:
22.94x
EV / Revenue:
2.72x
PEG ratio (5yr expected):
1.10x
EV / Free cash flow:
36.77x
Price / Operating cash flow:
34.90x
Enterprise value / EBITDA:
18.41x
Gross Profit (TTM):
$232M
Return On Assets:
6.11%
Net Income Margin (TTM):
6.87%
Return On Equity:
12.82%
Return On Invested Capital:
7.46%
Operating Margin:
10.95%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $465.2M | $508.6M | $559.8M | $137.9M | $130.1M | |
| Gross Profit | $182.1M | $211.7M | $232M | $57.6M | $56.1M | |
| Operating Income | $46.2M | $62.6M | $72M | $15.1M | $14.3M | |
| EBITDA | $58.2M | $71.8M | $82.7M | $14.5M | $18.7M | |
| Diluted EPS | $0.61 | $1.01 | $0.95 | $0.18 | $0.23 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $140.1M | $143.7M | $198.5M | $269.3M | $332.5M | |
| Total Assets | $300.5M | $321M | $389M | $599.4M | $656.3M | |
| Current Liabilities | $71.2M | $75.9M | $75.4M | $95.6M | $93.7M | |
| Total Liabilities | $284.5M | $225.1M | $219.5M | $328.7M | $338.7M | |
| Total Equity | $16M | $95.9M | $169.5M | $270.7M | $317.6M | |
| Total Debt | $211.9M | $156.4M | $146.2M | $215.8M | $220.5M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $50.2M | $62.6M | $47M | $2.1M | $17.4M | |
| Cash From Investing | -$39.5M | -$148.6M | -$6.1M | -$142.6M | -$1.3M | |
| Cash From Financing | $28.1M | $124.4M | $5.1M | $139.8M | -$7.8M | |
| Free Cash Flow | $45.9M | $55.3M | $41.4M | $794K | $16.1M | |
CDRE
Sector
Market Cap
$1.4B
$610M
Price % of 52-Week High
87.61%
77.25%
Dividend Yield
1.03%
0%
Shareholder Yield
-1.64%
2.42%
1-Year Price Total Return
18.03%
-5.27%
Beta (5-Year)
--
0.777
Dividend yield:
1.03%
Annualized payout:
$0.35
Payout ratio:
37.76%
Growth streak:
1 years
Technicals
8-day SMA
Sell
Level
$35.57
200-day SMA
Buy
Level
$34.45
Bollinger Bands (100)
Buy
Level
30.2 - 36.22
Chaikin Money Flow
Buy
Level
1.6M
20-day SMA
Buy
Level
$31.98
Relative Strength Index (RSI14)
Buy
Level
64.67
ADX Line
Buy
Level
25.54
Williams %R
Neutral
Level
-22.8944
50-day SMA
Buy
Level
$31.52
MACD (12, 26)
Buy
Level
1.36
25-day Aroon Oscillator
Buy
Level
48
On Balance Volume
Neutral
Level
14.1M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.932)
Buy
CA Score
(Annual)
Level (0.3214)
Sell
Beneish M-Score
(Annual)
Level (-1.7802)
Buy
Momentum Score
Level (4)
Buy
Ohlson Score
Level (-0.0164)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (8)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Cadre Holdings Inc is engaged in the design and manufacture of a diversified product portfolio of critical safety and survivability equipment to protect first responders, federal agencies, outdoor recreation, and personal protection markets. The Company’s equipment provides critical protection to allow its users to safely and securely perform their duties and protect those around them in hazardous or life-threatening situations. Its operations are comprised of two reportable segments: Products and Distribution.
Stock Forecast FAQ
In the current month, CDRE has received 4 Buy ratings 1 Hold ratings, and 0 Sell ratings. The CDRE average analyst price target in the past 3 months is $43.83.
-
Where Will Cadre Holdings Stock Be In 1 Year?
According to analysts, the consensus estimate is that Cadre Holdings share price will rise to $43.83 per share over the next 12 months.
-
What Do Analysts Say About Cadre Holdings?
Analysts are divided on their view about Cadre Holdings share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Cadre Holdings is a Sell and believe this share price will drop from its current level to $40.00.
-
What Is Cadre Holdings's Price Target?
The price target for Cadre Holdings over the next 1-year time period is forecast to be $43.83 according to 5 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is CDRE A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Cadre Holdings is a Buy. 4 of 5 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of CDRE?
You can purchase shares of Cadre Holdings via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Cadre Holdings shares.
-
What Is The Cadre Holdings Share Price Today?
Cadre Holdings was last trading at $35.38 per share. This represents the most recent stock quote for Cadre Holdings. Yesterday, Cadre Holdings closed at $35.29 per share.
-
How To Buy Cadre Holdings Stock Online?
In order to purchase Cadre Holdings stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Mobileye Might Be Wall Street’s Next Big Surprise
The trend to automate vehicles started long ago when adding…
Why Is Rigetti Stock Going Up?
Quantum computing firm Rigetti Computing (NASDAQ:RGTI) has been one of…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 38x
Buy
71
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 46x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Alerts
Buy
81
SMLR alert for May 19
Semler Scientific [SMLR] is up 5.85% over the past day.
Sell
25
GLOB alert for May 19
Globant SA [GLOB] is up 4.02% over the past day.
Buy
94
HIMS alert for May 19
Hims & Hers Health [HIMS] is down 3.57% over the past day.
